Pornpimol Rianthavorn1, Pantipa Boonyapapong. 1. Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, 1873 Rama 4 Road, Pathumwan, Bangkok, 10330, Thailand. Pornpimol.R@chula.ac.th
Abstract
BACKGROUND: Vitamin D insufficiency is related to erythropoietin resistance in chronic kidney disease (CKD). This study was conducted to evaluate the effect of ergocalciferol on the dose of erythrocyte-stimulating agent (ESA) administered to children with CKD stage 5 and vitamin D insufficiency. METHODS:Twenty patients aged <18 years with CKD stages 5 or 5D and vitamin D insufficiency were divided into two groups. During the 12-week study, ten patients received oral ergocalciferol (treatment) whereas the other ten patients did not (control). The ESA dosage was recorded monthly. RESULTS: There were no significant differences in demographic data, ESA dosages, and laboratory data, including corrected calcium, phosphorus, parathyroid hormone, hemoglobin, ferritin, 25-hydroxyvitamin D (25D), and transferrin saturation levels, between the two groups at baseline. At the completion of the study, serum 25D levels in the treatment group were significantly increased from baseline (p = 0.02) and were significantly higher than the serum 25D levels in the controls (p < 0.005). The ESA dosage in the treatment group was significantly decreased when compared to baseline (p = 0.04). CONCLUSIONS: Vitamin D deficiency should be routinely detected and treated. Our results show that the administration of ergocalciferol in conjunction with 1,25-dihydroxyvitamin D3 reduced the dose of ESA required to treat children with CKD stages 5 and 5D and may decrease erythropoietin resistance.
RCT Entities:
BACKGROUND:Vitamin Dinsufficiency is related to erythropoietin resistance in chronic kidney disease (CKD). This study was conducted to evaluate the effect of ergocalciferol on the dose of erythrocyte-stimulating agent (ESA) administered to children with CKD stage 5 and vitamin Dinsufficiency. METHODS: Twenty patients aged <18 years with CKD stages 5 or 5D and vitamin Dinsufficiency were divided into two groups. During the 12-week study, ten patients received oral ergocalciferol (treatment) whereas the other ten patients did not (control). The ESA dosage was recorded monthly. RESULTS: There were no significant differences in demographic data, ESA dosages, and laboratory data, including corrected calcium, phosphorus, parathyroid hormone, hemoglobin, ferritin, 25-hydroxyvitamin D (25D), and transferrin saturation levels, between the two groups at baseline. At the completion of the study, serum 25D levels in the treatment group were significantly increased from baseline (p = 0.02) and were significantly higher than the serum 25D levels in the controls (p < 0.005). The ESA dosage in the treatment group was significantly decreased when compared to baseline (p = 0.04). CONCLUSIONS:Vitamin D deficiency should be routinely detected and treated. Our results show that the administration of ergocalciferol in conjunction with 1,25-dihydroxyvitamin D3 reduced the dose of ESA required to treat children with CKD stages 5 and 5D and may decrease erythropoietin resistance.
Authors: Justine Bacchetta; Joshua J Zaritsky; Jessica L Sea; Rene F Chun; Thomas S Lisse; Kathryn Zavala; Anjali Nayak; Katherine Wesseling-Perry; Mark Westerman; Bruce W Hollis; Isidro B Salusky; Martin Hewison Journal: J Am Soc Nephrol Date: 2013-11-07 Impact factor: 10.121
Authors: Meredith A Atkinson; Stephen P Juraschek; Michael S Bertenthal; Barbara Detrick; Susan L Furth; Edgar R Miller Journal: Pediatr Nephrol Date: 2016-12-24 Impact factor: 3.714
Authors: Luigi Francesco Morrone; Pergiorgio Bolasco; Corrado Camerini; Giuseppe Cianciolo; Adamasco Cupisti; Andrea Galassi; Sandro Mazzaferro; Domenico Russo; Luigi Russo; Mario Cozzolino Journal: J Nephrol Date: 2016-04-09 Impact factor: 3.902
Authors: Carrie E Thomas; Ronnie Guillet; Ruth A Queenan; Elizabeth M Cooper; Tera R Kent; Eva K Pressman; Francoise M Vermeylen; Mark S Roberson; Kimberly O O'Brien Journal: Am J Clin Nutr Date: 2015-10-07 Impact factor: 7.045
Authors: Dana C Miskulin; Karen Majchrzak; Hocine Tighiouart; Richard S Muther; Toros Kapoian; Doug S Johnson; Daniel E Weiner Journal: J Am Soc Nephrol Date: 2015-12-17 Impact factor: 10.121